JP7422072B2 - 細胞培養方法 - Google Patents

細胞培養方法 Download PDF

Info

Publication number
JP7422072B2
JP7422072B2 JP2020529609A JP2020529609A JP7422072B2 JP 7422072 B2 JP7422072 B2 JP 7422072B2 JP 2020529609 A JP2020529609 A JP 2020529609A JP 2020529609 A JP2020529609 A JP 2020529609A JP 7422072 B2 JP7422072 B2 JP 7422072B2
Authority
JP
Japan
Prior art keywords
cysteine
cystine
cell culture
seq
recombinant protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020529609A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021503938A5 (https=
JP2021503938A (ja
Inventor
シュバリエ、バレンティン
コチャノウスキ、ナディーン
マルフェッテ、レティシア
アドルフ キャロル クール、ビンセント
Original Assignee
ユーシービー バイオファルマ エスアールエル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60629439&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7422072(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ユーシービー バイオファルマ エスアールエル filed Critical ユーシービー バイオファルマ エスアールエル
Publication of JP2021503938A publication Critical patent/JP2021503938A/ja
Publication of JP2021503938A5 publication Critical patent/JP2021503938A5/ja
Application granted granted Critical
Publication of JP7422072B2 publication Critical patent/JP7422072B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
JP2020529609A 2017-12-01 2018-11-29 細胞培養方法 Active JP7422072B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17204978.5A EP3492582A1 (en) 2017-12-01 2017-12-01 Cell culture methods
EP17204978.5 2017-12-01
PCT/EP2018/083010 WO2019106091A1 (en) 2017-12-01 2018-11-29 Cell culture methods

Publications (3)

Publication Number Publication Date
JP2021503938A JP2021503938A (ja) 2021-02-15
JP2021503938A5 JP2021503938A5 (https=) 2021-11-04
JP7422072B2 true JP7422072B2 (ja) 2024-01-25

Family

ID=60629439

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020529609A Active JP7422072B2 (ja) 2017-12-01 2018-11-29 細胞培養方法

Country Status (14)

Country Link
US (1) US11859203B2 (https=)
EP (2) EP3492582A1 (https=)
JP (1) JP7422072B2 (https=)
KR (1) KR20200092348A (https=)
CN (1) CN111417715B (https=)
BR (1) BR112020010473A2 (https=)
CA (1) CA3083680A1 (https=)
EA (1) EA202091349A1 (https=)
ES (1) ES2963653T3 (https=)
HR (1) HRP20231175T1 (https=)
HU (1) HUE063812T2 (https=)
PL (1) PL3717631T3 (https=)
SG (1) SG11202004935UA (https=)
WO (1) WO2019106091A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3492582A1 (en) 2017-12-01 2019-06-05 UCB Biopharma SPRL Cell culture methods
CN112391350A (zh) * 2020-10-30 2021-02-23 北京双鹭药业股份有限公司 高效表达抗egfr单克隆抗体细胞的筛选培养方法
GB202105424D0 (en) 2021-04-16 2021-06-02 UCB Biopharma SRL Cell culture processes
EP4166651A1 (en) 2021-10-18 2023-04-19 Evonik Operations GmbH Methods and composition to increase cellular glutathione level
WO2023067626A1 (en) * 2021-10-20 2023-04-27 Dr. Reddy's Laboratories Limited A cell culture process to produce an antibody composition
EP4484567A4 (en) * 2022-02-21 2026-04-01 Chugai Pharmaceutical Co Ltd PERFUSION CULTURE METHOD
WO2024024720A1 (ja) * 2022-07-25 2024-02-01 味の素株式会社 細胞培養用の培地

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008033517A2 (en) 2006-09-13 2008-03-20 Abbott Laboratories Cell culture improvements
WO2017186654A1 (en) 2016-04-28 2017-11-02 Merck Patent Gmbh Method for reducing the trisulfide level in proteins

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
EP1482031B1 (en) 1996-08-30 2015-10-28 Life Technologies Corporation Serum-free mammalian cell culture medium, and uses thereof
CN101332157B (zh) * 1998-10-09 2012-01-11 味之素株式会社 半胱氨酸衍生物
KR20050070512A (ko) 2003-12-30 2005-07-07 삼성정밀화학 주식회사 재조합 단백질의 생산성을 증가시키는 무혈청 배지 및동물세포 배양방법
EP2500415A1 (en) 2006-09-13 2012-09-19 Abbott Laboratories Cell culture improvements
AU2011246502B2 (en) 2010-04-26 2014-08-28 Novartis Ag Improved cell cultivation process
WO2013158275A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Cell culture methods to reduce acidic species
US20130281355A1 (en) 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
GB201208367D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product
BR112016027797A2 (pt) 2014-06-18 2017-10-31 Medimmune Llc métodos e meios de cultura de células compreendendo n-acetilcisteína
EP3492582A1 (en) 2017-12-01 2019-06-05 UCB Biopharma SPRL Cell culture methods

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008033517A2 (en) 2006-09-13 2008-03-20 Abbott Laboratories Cell culture improvements
WO2017186654A1 (en) 2016-04-28 2017-11-02 Merck Patent Gmbh Method for reducing the trisulfide level in proteins

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Biotechnol Prog, 2005 Jul 7, vol. 21, no. 4, pp. 1154-1164
FEBS Lett, 2002 Aug 5, vol. 526, no. 1-3, pp. 106-110
J Biotechnol, 2015 Dec 2, vol. 218, pp. 53-63
MAbs. 2017(Epub 2017 Jul 25), vol. 9, no. 6, pp. 889-897

Also Published As

Publication number Publication date
PL3717631T3 (pl) 2024-03-04
EA202091349A1 (ru) 2020-08-20
US20200308536A1 (en) 2020-10-01
SG11202004935UA (en) 2020-06-29
EP3717631A1 (en) 2020-10-07
US11859203B2 (en) 2024-01-02
CA3083680A1 (en) 2019-06-06
JP2021503938A (ja) 2021-02-15
HRP20231175T1 (hr) 2024-01-19
BR112020010473A2 (pt) 2020-11-24
KR20200092348A (ko) 2020-08-03
WO2019106091A1 (en) 2019-06-06
EP3717631B1 (en) 2023-08-30
CN111417715B (zh) 2024-08-27
CN111417715A (zh) 2020-07-14
HUE063812T2 (hu) 2024-02-28
EP3717631C0 (en) 2023-08-30
ES2963653T3 (es) 2024-04-01
EP3492582A1 (en) 2019-06-05

Similar Documents

Publication Publication Date Title
JP7422072B2 (ja) 細胞培養方法
JP5907928B2 (ja) 抗老化性の化合物を使用する蛋白の生成方法
JP7406593B2 (ja) 細胞培養方法
JP7842737B2 (ja) 細胞培養プロセス
US20240425894A1 (en) Cell culture processes
HK40114294A (zh) 细胞培养方法
BR122024024868A2 (pt) Métodos de cultura celular
EA044551B1 (ru) Способы культивирования клеток

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210921

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230310

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230601

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231030

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240110

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240115

R150 Certificate of patent or registration of utility model

Ref document number: 7422072

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150